Intensity Therapeutics, Inc. (NASDAQ: INTS) announced a 1‑for‑25 reverse stock split of its common stock. The split will take effect at 4:01 p.m. Eastern Time on February 18, 2026, reducing the number of shares outstanding from roughly 63.3 million to about 2.53 million. The company’s ticker symbol will remain INTS on the Nasdaq Capital Market after the split.
The reverse split is intended to raise the per‑share trading level and help the company maintain compliance with Nasdaq’s minimum bid‑price requirement. Intensity Therapeutics has been granted extensions to regain compliance, with a deadline of June 1, 2026. The move is a common tactic for companies whose per‑share level has fallen below the $1.00 threshold.
The company’s financial profile underscores the need for the split. Intensity Therapeutics reported a negative earnings per share of –$0.63 and a return on equity of –380.13 %. Revenue growth has stalled, and the company’s Altman Z‑Score and Piotroski F‑Score are low, signaling potential financial distress. Despite these challenges, the company maintains a strong current ratio of 3.6 and minimal debt, with a debt‑to‑equity ratio of 0.02.
Investors reacted negatively to the announcement, reflecting concerns that the reverse split signals underlying weakness rather than a strategic improvement. The move highlights the company’s struggle to meet Nasdaq listing requirements organically.
Intensity Therapeutics continues to focus on its DfuseRx technology platform and its lead product candidate, INT230‑6, for cancer treatment. The company has raised $4 million in a registered direct offering and an at‑the‑market program to extend its cash runway and support ongoing clinical development.
The reverse split will adjust the exercise and conversion prices of outstanding stock options, warrants, and convertible securities, but it will not affect the company’s total equity value.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.